Table 4.

Breakdown of total costs over the time horizon (base-case scenario)

Cost type (£)	Fulvestrant	Anastrozole	Letrozole	Tamoxifen
Disease management costs
Progression free	5419.25	3736.94	4219.31	2576.71
Progressive disease	20,167.23	19,861.58	14,919.84	21,967.73
Terminal care	3773.58	3886.13	3937.51	3924.96
Treatment-related costs
Acquisition	15,840.54	15.19	34.98	21.25
Administration	2457.65	732.76	811.00	560.71
Subsequent treatmenta	1660.59	2287.40	2286.17	2968.04
AEsb	112.01	44.13	125.01	280.61
Relative dose intensity/compliance	1.00c/0.99d	0.99	1.00e	1.00e
Total costs	49,430.86	30,564.12	26,333.82	32,300.02

Costs are in 2016 British pounds sterling

AE adverse event

^aCosts for subsequent second- and third-line treatments post-progression, categorized into endocrine therapies, targeted therapies, and chemotherapies, and taking into account duration of treatment

^bManagement of grade ≥ 3 AEs experienced by ≥ 2% of patients

^cFirst 4 weeks

^dAfter first 4 weeks

^eAssumption (data not available)